Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives

Long T Phan,1,2 Geoffrey K Broadhead,1,3 Thomas H Hong,1 Andrew A Chang1,3 1Sydney Retina, Sydney, New South Wales, Australia; 2Discipline of Orthoptics, University of Technology Sydney, Sydney, New South Wales, Australia; 3Save Sight Institute, The University of Sydney, Sydney, New South Wales, Aus...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Phan LT, Broadhead GK, Hong TH, Chang AA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	age-related macular degeneration anti-vegf visual acuity demographic genetic anatomic Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/cc9a5bd4700045f3a39888f0f967a671
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cc9a5bd4700045f3a39888f0f967a671
record_format	dspace
spelling	oai:doaj.org-article:cc9a5bd4700045f3a39888f0f967a6712021-12-02T18:49:39ZPredictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives1177-5483https://doaj.org/article/cc9a5bd4700045f3a39888f0f967a6712021-08-01T00:00:00Zhttps://www.dovepress.com/predictors-of-visual-acuity-after-treatment-of-neovascular-age-related-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Long T Phan,1,2 Geoffrey K Broadhead,1,3 Thomas H Hong,1 Andrew A Chang1,3 1Sydney Retina, Sydney, New South Wales, Australia; 2Discipline of Orthoptics, University of Technology Sydney, Sydney, New South Wales, Australia; 3Save Sight Institute, The University of Sydney, Sydney, New South Wales, AustraliaCorrespondence: Andrew A ChangSydney Retina, Level 13, Park House, 187 Macquarie Street, Sydney, 2000, New South Wales, AustraliaTel +61 2 9221 3755Fax +61 2 9221 1637Email achang@sydneyretina.com.auAbstract: Visual acuity is a key outcome measure in the treatment of neovascular age-related macular degeneration (nAMD) using anti-vascular endothelial growth factor agents. Large variations in visual responses between individuals within clinical trials and real-world studies may relate to underlying differences in patient and treatment factors. Most notably, a better baseline visual acuity, younger age and smaller choroidal neovascularization lesion size have been strongly associated with achieving better visual outcomes. In addition, there is emerging evidence for other roles including genetic factors and anatomical variables such as fluid status. Apart from patient-related factors, treatments that favor a higher number of injections tend to provide better visual outcomes. Overall, the identification of predictive factors does not currently play an essential role in the clinical management of patients with nAMD. However, they have allowed for the understanding that early detection, timely management and close monitoring of the disease are required to achieve optimal visual outcomes. Further investigation into predictive factors alongside the development of novel therapeutic agents may one day provide a means to accurately predict patient outcomes. Treatment regimens that offer flexible dosing patterns such as the treat-and-extend strategy currently provide a degree of personalization during treatment.Keywords: age-related macular degeneration, anti-VEGF, visual acuity, demographic, genetic, anatomicPhan LTBroadhead GKHong THChang AADove Medical Pressarticleage-related macular degenerationanti-vegfvisual acuitydemographicgeneticanatomicOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 3351-3367 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	age-related macular degeneration anti-vegf visual acuity demographic genetic anatomic Ophthalmology RE1-994
spellingShingle	age-related macular degeneration anti-vegf visual acuity demographic genetic anatomic Ophthalmology RE1-994 Phan LT Broadhead GK Hong TH Chang AA Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives
description	Long T Phan,1,2 Geoffrey K Broadhead,1,3 Thomas H Hong,1 Andrew A Chang1,3 1Sydney Retina, Sydney, New South Wales, Australia; 2Discipline of Orthoptics, University of Technology Sydney, Sydney, New South Wales, Australia; 3Save Sight Institute, The University of Sydney, Sydney, New South Wales, AustraliaCorrespondence: Andrew A ChangSydney Retina, Level 13, Park House, 187 Macquarie Street, Sydney, 2000, New South Wales, AustraliaTel +61 2 9221 3755Fax +61 2 9221 1637Email achang@sydneyretina.com.auAbstract: Visual acuity is a key outcome measure in the treatment of neovascular age-related macular degeneration (nAMD) using anti-vascular endothelial growth factor agents. Large variations in visual responses between individuals within clinical trials and real-world studies may relate to underlying differences in patient and treatment factors. Most notably, a better baseline visual acuity, younger age and smaller choroidal neovascularization lesion size have been strongly associated with achieving better visual outcomes. In addition, there is emerging evidence for other roles including genetic factors and anatomical variables such as fluid status. Apart from patient-related factors, treatments that favor a higher number of injections tend to provide better visual outcomes. Overall, the identification of predictive factors does not currently play an essential role in the clinical management of patients with nAMD. However, they have allowed for the understanding that early detection, timely management and close monitoring of the disease are required to achieve optimal visual outcomes. Further investigation into predictive factors alongside the development of novel therapeutic agents may one day provide a means to accurately predict patient outcomes. Treatment regimens that offer flexible dosing patterns such as the treat-and-extend strategy currently provide a degree of personalization during treatment.Keywords: age-related macular degeneration, anti-VEGF, visual acuity, demographic, genetic, anatomic
format	article
author	Phan LT Broadhead GK Hong TH Chang AA
author_facet	Phan LT Broadhead GK Hong TH Chang AA
author_sort	Phan LT
title	Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives
title_short	Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives
title_full	Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives
title_fullStr	Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives
title_full_unstemmed	Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives
title_sort	predictors of visual acuity after treatment of neovascular age-related macular degeneration – current perspectives
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/cc9a5bd4700045f3a39888f0f967a671
work_keys_str_mv	AT phanlt predictorsofvisualacuityaftertreatmentofneovascularagerelatedmaculardegenerationndashcurrentperspectives AT broadheadgk predictorsofvisualacuityaftertreatmentofneovascularagerelatedmaculardegenerationndashcurrentperspectives AT hongth predictorsofvisualacuityaftertreatmentofneovascularagerelatedmaculardegenerationndashcurrentperspectives AT changaa predictorsofvisualacuityaftertreatmentofneovascularagerelatedmaculardegenerationndashcurrentperspectives
_version_	1718377590412017664

Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration &ndash; Current Perspectives

Ejemplares similares

Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives